BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well

Bayer’s Q3 core EPS fell 36.7% year over year to $0.11 per ADR, below the $0.13 consensus, while reported sales rose 4.1% to $11.57 billion but missed the $11.70 billion estimate. Pharmaceuticals sales grew 6.4%, led by Nubeqa (+58.3%) and Kerendia (+64.9%), but Crop Science sales declined 2.4% and generic competition pressured established drugs. Bayer raised 2026 EBITDA-before-special-items guidance to €9.8–€10.3 billion from €9.6–€10.1 billion and lifted its Pharmaceuticals margin outlook to 25–27% from 23–25%; core EPS guidance remains €4.30–€4.80.

Analysis

The key tension is weak earnings conversion beneath a better operating-profit outlook: stronger Pharmaceuticals profitability lifted EBITDA guidance, but EPS guidance stayed unchanged and quarterly core EPS fell sharply. Until cash generation and EPS respond, the guidance increase is a lower-quality catalyst than the headline suggests; verify cash flow, net debt, and the tax/financial-result bridge before underwriting a rerating.

Pharma growth is also concentrated against continuing erosion in older products. Nubeqa and Kerendia can improve the mix, but their growth must persist at scale to offset Eylea and Xarelto losses; approvals and review milestones are options, not yet proof of material near-term revenue. In Crop Science, weather may normalize, but generic herbicide pricing and regulatory friction are less readily reversed. That makes a simple weather-rebound thesis incomplete and leaves Bayer exposed to further mix and margin pressure.

For Regeneron, do not read Bayer’s reported Eylea decline as a direct read-through to U.S. product sales: the article assigns U.S. net sales to Regeneron and Bayer’s sales to markets outside the U.S. Shared-product competition remains a potential global headwind, but the geographic split matters. Bayer’s year-to-date outperformance raises the bar for incremental good news; absent valuation and cash-flow data, the mixed quarter does not support a high-conviction directional short.

Key Decisions for Investors

• Near term: avoid chasing BAYN after its prior outperformance; keep exposure neutral-to-underweight until the next update demonstrates that the higher Pharma margin outlook is translating into EPS and free cash flow.
• Set a 1–3 month alert for the EPS-to-EBITDA bridge, cash conversion, and net-debt trajectory. A further EPS-guidance reduction or weakening cash conversion would strengthen the underweight case; sustained conversion alongside Pharma margin delivery would invalidate it.
• Treat Crop Science recovery as conditional: monitor generic herbicide pricing, regional weather, and regulatory developments. A weather rebound alone is not sufficient confirmation if pricing pressure persists.
• Do not use Bayer’s Eylea decline alone to short REGN. Reassess Regeneron only against U.S. sales trends and product-level competitive data; the article does not establish deterioration in that market.